Jeff Settleman

Senior Vice President and Chief Scientific Officer, Oncology and Research Development; Pfizer

Dr. Jeff Settleman is the Chief Scientific Officer for Oncology Research and Development and  serves as the La Jolla site head. Dr. Settleman leads all oncology research from the beginning  stages of discovery to proof-of-concept clinical studies. Dr. Settleman is an internationally  recognized leader in molecularly targeted cancer therapeutics, the epigenetics of cancer drug  resistance, and personalized cancer medicine. Dr. Settleman held numerous notable positions  in both academic research and drug discovery before joining the Pfizer team.

Prior to his current role, Dr. Settleman served as Distinguished Principal Investigator and Head  of Oncology Research at Calico Life Sciences. Prior to Calico, Dr. Settleman led Discovery  Oncology at Genentech. Dr. Settleman served as a professor at the Harvard School of Medicine  for 18 years and during his tenure he was named the Laurel Schwartz Professor of Oncology.  During that same timeframe, Dr. Settleman served as Director of the Center for Molecular  Therapeutics and Scientific Director of the Massachusetts General Hospital Cancer Center and  led the Cancer Cell Biology program of the Dana-Farber/Harvard Cancer Center.

Dr. Settleman’s scientific career began at the Whitehead Institute for Biomedical Research at  MIT where he was a postdoctoral fellow in Oncology and Cancer Biology. Dr. Settleman  received his Doctor of Philosophy in Genetics from Yale University and his Bachelor of Arts in  Neuroscience from the University of Pennsylvania. He is the author of over 240 peer-reviewed  publications, many of which have appeared in Cell, Science and Nature.

Sign Up Now

Register Now

Tickets are going fast -- reserve your seat at the JEL Conference today!